A subscription to JoVE is required to view this content. Sign in or start your free trial.
The present protocol establishes and characterizes a patient-derived xenograft (PDX) model of anaplastic thyroid carcinoma (ATC) and head and neck squamous cell carcinoma (HNSCC), as PDX models are rapidly becoming the standard in the field of translational oncology.
Patient-derived xenograft (PDX) models faithfully preserve the histological and genetic characteristics of the primary tumor and maintain its heterogeneity. Pharmacodynamic results based on PDX models are highly correlated with clinical practice. Anaplastic thyroid carcinoma (ATC) is the most malignant subtype of thyroid cancer, with strong invasiveness, poor prognosis, and limited treatment. Although the incidence rate of ATC accounts for only 2%-5% of thyroid cancer, its mortality rate is as high as 15%-50%. Head and neck squamous cell carcinoma (HNSCC) is one of the most common head and neck malignancies, with over 600,000 new cases worldwide each year. Herein, detailed protocols are presented to establish PDX models of ATC and HNSCC. In this work, the key factors influencing the success rate of model construction were analyzed, and the histopathological features were compared between the PDX model and the primary tumor. Furthermore, the clinical relevance of the model was validated by evaluating the in vivo therapeutic efficacy of representative clinically used drugs in the successfully constructed PDX models.
The PDX model is an animal model in which human tumor tissue is transplanted into immunodeficient mice and grows in the environment provided by the mice1. Traditional tumor cell line models suffer from several disadvantages, such as the lack of heterogeneity, the inability to retain the tumor microenvironment, the vulnerability to genetic variations during repeated in vitro passages, and the poor clinical application2,3. The main drawbacks of genetically engineered animal models are the potential loss of the genomic features of human tumors, the introduction of new unknown muta....
All the animal experiments were performed in accordance with the Association for Assessment and Accreditation of Laboratory Animal Care guidelines and protocols approved by the Institutional Animal Care and Use Committee of West China Hospital, Sichuan University. NOD-SCID immunodeficient mice aged 4-6 weeks old (of both sexes) and female Balb/c nude mice aged 4-6 weeks old were used for the present study. The animals were obtained from a commercial source (see Table of Materials). The ethics committee o.......
A total of 18 thyroid cancer specimens were transplanted, and five PDX models of thyroid cancer were successfully constructed (27.8% tumor take rate), including four cases of undifferentiated thyroid cancers and one case of anaplastic thyroid cancer. The correlation between the success rate of model construction and the age, gender, tumor diameter, tumor grade, and differentiation were analyzed. Although the model success rate of grade 4 tumor samples was higher than for samples with lower grades, and the success rate of.......
This study has successfully established the subcutaneous PDX models of ATC and HNSCC. There are many aspects to pay attention to during the process of PDX model construction. When the tumor tissue is separated from the patient, it should be put into the ice box and sent to the laboratory for inoculation as soon as possible. After the tumor arrives at the laboratory, the operator must pay attention to maintaining a sterile field and practice aseptic procedures. For needle biopsy samples, because the tumor tissue is partic.......
This work was supported by the Sichuan Province Science and Technology Support Program (Grant Nos. 2019JDRC0019 and 2021ZYD0097), the 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University (Grant No. ZYJC18026), the 1.3.5 project for disciplines of excellence-Clinical Research Incubation Project, West China Hospital, Sichuan University (Grant No. 2020HXFH023), the Fundamental Research Funds for the Central Universities (SCU2022D025), the International Cooperation Project of Chengdu Science and Technology Bureau (Grant No. 2022-GH02-00023-HZ), the Innovation Spark Project of Sichuan University (Grant No. 2019SCUH0015), and the Talent Train....
Name | Company | Catalog Number | Comments |
2.4 mm x 2.0 mm trocar | Shenzhen Huayang Biotechnology Co., Ltd | 18-9065 | |
Balb/c nude mice | Beijing Vital River Laboratory Animal Technology Co., Ltd. | 401 | |
Biosafety cabinet | Suzhou Antai | BSC-1300IIA2 | |
Blade | Shenzhen Huayang Biotechnology Co., Ltd | 18-0823 | |
Centrifuge tube | Corning | 430791/430829 | |
Cryopreservation tube | Chengdu Dianrui Experimental Instrument Co., Ltd | / | |
Custodiol HTK-Solution | Custodiol | 2103417 | |
Dimethyl sulfoxide(DMSO) | SIGMA-ALORICH | D5879-500mL | |
Electronic balance | METTLER | ME104 | |
Electronic digital caliper | Chengdu Chengliang Tool Group Co., Ltd | 0-220 | |
fetal bovine serum(FBS) | VivaCell | C04001-500 | |
IBM SPSS Statistics 26 | IBM | ||
Ketamine | Jiangsu Zhongmu Beikang Pharmaceutical Co., Ltd | 100761663 | |
Lenvatinib | ApexBio | A2174 | |
NOD SCID immunodeficient mice | Beijing Vital River Laboratory Animal Technology Co., Ltd. | 406 | |
Pen-Strep Solution | Biological Industries | 03-03101BCS | |
Petri dish | WHB | WHB-60/WHB-100 | |
Saline | Sichuan Kelun | W220051705 | |
Scissor | Shenzhen Huayang Biotechnology Co., Ltd | 18-0110 | |
Tweezer | Shenzhen Huayang Biotechnology Co., Ltd | 18-1241 | |
Vet ointment | Pfizer Inc. | P10015353 | |
Xylazine | Dunhua Shengda Animal Medicine Co., Ltd | 070031777 |
This article has been published
Video Coming Soon
ABOUT JoVE
Copyright © 2024 MyJoVE Corporation. All rights reserved